Vision Benefits Company XP Health Raises $17.1M+ in Digital Health Funding
XP Health, a company developing a digital vision benefits platform, raised $17.1 million in a Series A funding round led by HC9 Ventures, Valor Capital Group and ManchesterStory.
Other investors include Core Innovation Capital, GSR Ventures, Canvas Ventures, Plug and Play, CameronVC, Ken Goulet, Kevin Hill, Jeff Epstein and Brett Rochkind. This recent round of funding follows a $5.5 million increase in 2021.
“This round of funding allows us to strengthen the functionality of the platform and deliver an exceptional customer experience in the most affordable way to employers, insurance companies and employees,” said Antonio Moraes, co-founder and CEO of XP Health, in a press release.
“We have a game-changing offering on how people access and experience employee benefits – with the ultimate goal of positively impacting hundreds of millions of lives through high-quality health benefits. quality, accessible and affordable.”
Lung health company Optellum has announced the closing of a $14 million Series A funding round led by UK venture capital firm Mercia with participation from US firms Intuitive Ventures and Black Opal.
Its Virtual Nodule Clinic software is used to track, assess and characterize nodules in the lungs. The company has reached FDA clearance in USA, CE-MDR in EU and UKCA in UK for the platform. A CE marking certificate (CE-MDR) is required to market medical devices in the EU. The UK Conformity Assessed mark indicates that a product complies with the applicable requirements for sale in Great Britain.
“[Virtual Nodule Clinic] can help doctors identify and track at-risk patients and optimally diagnose signs of lung cancer early – so treatment can be started sooner for patients with tumors and to minimize invasive procedures such as biopsies on benign lesions,” the company said in a press release.
The company behind the Cionic Neural Sleeve has received $12.5 million in a Series A funding round led by BlueRun Ventures, with participation from EPIC Ventures, LDV Capital, Caffeinated Capital, and JobsOhio Growth Capital Fund.
This funding round follows that of Cionic Neural Sleeve FDA clearance in early 2022. Leg-worn device provides electrical stimulation so people with foot drop and muscle weakness can walk more easily. Cionic has so far received $23 million to build its human mobility-focused platform.
The new fundraising will help the company expand manufacturing and delivery of its mobility technology, and accelerate research trials and commercialization of its products for new indications.
“Forward-looking investors realize we must act today, and we are proud to be supported by a group of investors who recognize the need for better solutions and have joined us in our mission to redefine human mobility. “, Cionic said founder and CEO Jeremiah Robison in a statement.
Kaleidoscope, a cloud-based research platform that maps data usage by R&D teams, has consolidated a $6 million seed funding round.
It was co-led by Hummingbird Ventures and Dimension, with participation from SV Angel, Hawktail, Caffeinated Capital and individual investors.
The funding will help the company further develop the platform product and expand the company’s team, particularly with software engineers.
“The way people work in research is changing. Kaleidoscope bridges the gap between teams on a platform that integrates with other software tools. The funding will allow us to provide the best product and user experience to make research more collaborative, replicable and scalable. Bogdan Knezevic, CEO and co-founder of Kaleidoscope, said in a statement.
Arcascope, a health technology company specializing in circadian rhythm disruption, announced the closing of a $2.85 million funding round.
The round was led by Supermoon Capital, with participation from New Dominion Angels, Inflect Health, Inception Health, the Accelerate Blue Fund, the Monroe Brown Seed Fund, AIoT Health, HealthX Ventures and other angel investors.
Company Launches Circadian Rhythm Management Platform, Currently Accessible Through Smartphone App, Shift, to meet the sleep needs of shift workers.
Surge, a company developing machine learning technology to decode a patient’s blood sample to predict the risk of postoperative complications, announces $2.6 million round co-led by HCVC and Boutique Venture Partners , with the participation of Nicolas Godin.
The company has also been granted the exclusive license to Stanford University’s patented postoperative complication prediction technology, which includes more than 10 years of surgical risk prediction research. Surge has also signed a research agreement with Stanford aimed at developing biotechnological innovations.
This new round of funding will help the company further grow its team and conduct clinical studies with more hospitals.